995. A Murine Model of Klebsiella pneumoniae Gastrointestinal Colonization with Parenteral Vancomycin Administration. (4th December 2021)
- Record Type:
- Journal Article
- Title:
- 995. A Murine Model of Klebsiella pneumoniae Gastrointestinal Colonization with Parenteral Vancomycin Administration. (4th December 2021)
- Main Title:
- 995. A Murine Model of Klebsiella pneumoniae Gastrointestinal Colonization with Parenteral Vancomycin Administration
- Authors:
- Cheung, Bettina
Lebrun-Corbin, Marine
Hauser, Alan R - Abstract:
- Abstract: Background: As a leading cause of nosocomial infections, Klebsiella pneumoniae poses a significant threat due to its propensity to acquire resistance to many classes of antibiotics, including carbapenems. Gastrointestinal (GI) colonization by K. pneumoniae is a risk factor for subsequent infection as well as transmission to other patients. To study this crucial step in pathogenesis, we developed a mouse model of K. pneumoniae GI colonization using a clinically relevant parenteral antibiotic regimen. Methods: To improve the clinical relevance of our model, we elected to use intraperitoneal injections of vancomycin, one of the most highly utilized antibiotics in the United States. Results: To optimize dosage in C57bl/6 mice, we injected 20mg/kg, 350mg/kg, or vehicle (PBS) for three days prior to gastric gavage with 10 8 colony forming units (CFU) of a low-resistance strain of K. pneumoniae . The mice who received 350mg/kg (a mouse equivalent of a human dose of 1g/day calculated through the FDA guidelines for estimating safe dosing) shed about 10 7 CFU/g of feces at Day 7 while those receiving the lower dose or vehicle shed 10 4 CFU/g. Next, we compared 3- or 5-day pre-treatments with vancomycin prior to inoculation with an ST258 (epidemic carbapenem-resistant) strain. At Day 7 post-inoculation, mice who received 5 days shed 10 10 CFU/g feces while those who received vancomycin for 3 days or vehicle for 5 days (PBS) shed 10 6 or 10 4 CFU/g feces respectively. Thus, weAbstract: Background: As a leading cause of nosocomial infections, Klebsiella pneumoniae poses a significant threat due to its propensity to acquire resistance to many classes of antibiotics, including carbapenems. Gastrointestinal (GI) colonization by K. pneumoniae is a risk factor for subsequent infection as well as transmission to other patients. To study this crucial step in pathogenesis, we developed a mouse model of K. pneumoniae GI colonization using a clinically relevant parenteral antibiotic regimen. Methods: To improve the clinical relevance of our model, we elected to use intraperitoneal injections of vancomycin, one of the most highly utilized antibiotics in the United States. Results: To optimize dosage in C57bl/6 mice, we injected 20mg/kg, 350mg/kg, or vehicle (PBS) for three days prior to gastric gavage with 10 8 colony forming units (CFU) of a low-resistance strain of K. pneumoniae . The mice who received 350mg/kg (a mouse equivalent of a human dose of 1g/day calculated through the FDA guidelines for estimating safe dosing) shed about 10 7 CFU/g of feces at Day 7 while those receiving the lower dose or vehicle shed 10 4 CFU/g. Next, we compared 3- or 5-day pre-treatments with vancomycin prior to inoculation with an ST258 (epidemic carbapenem-resistant) strain. At Day 7 post-inoculation, mice who received 5 days shed 10 10 CFU/g feces while those who received vancomycin for 3 days or vehicle for 5 days (PBS) shed 10 6 or 10 4 CFU/g feces respectively. Thus, we chose 5 days of 350mg/kg vancomycin injection as our regimen for inducing robust GI colonization in mice. Finally, we tested the durability of colonization by following fecal shedding in mice up to Day 60 post-inoculation with a second ST258 strain. Shedding during the first 7 days occurs at about 10 10 CFU/g feces, and from day 14 to day 60 fecal loads are stable around 10 7 CFU/g feces. Results are comparable between male and female mice. Conclusion: In conclusion, we have developed a mouse model of robust, prolonged GI colonization with multiple strains of K. pneumoniae using controlled dosing of a clinically relevant antibiotic. This model may be used to study a key step in K. pneumoniae pathogenesis and infection prevention in the future. Disclosures: All Authors : No reported disclosures … (more)
- Is Part Of:
- Open forum infectious diseases. Volume 8(2021)Supplement 1
- Journal:
- Open forum infectious diseases
- Issue:
- Volume 8(2021)Supplement 1
- Issue Display:
- Volume 8, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 8
- Issue:
- 1
- Issue Sort Value:
- 2021-0008-0001-0000
- Page Start:
- S588
- Page End:
- S588
- Publication Date:
- 2021-12-04
- Subjects:
- Communicable diseases -- Periodicals
Medical microbiology -- Periodicals
Infection -- Periodicals
616.9 - Journal URLs:
- http://ofid.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/ofid/ofab466.1189 ↗
- Languages:
- English
- ISSNs:
- 2328-8957
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21265.xml